Specify a stock or a cryptocurrency in the search bar to get a summary
Kronos Bio Inc
KRONKronos Bio, Inc., a clinical-stage biopharmaceutical company, focuses on the discovery and development of therapeutics for various cancer and other serious diseases in the United States. Its lead product candidates are KB-0742, an oral cyclin dependent kinase 9 inhibitor for the treatment of MYC-amplified solid tumors, which is in phase 2 clinical trial; and KB-9558, a core oncogenic transcription factor that drives multiple myeloma. The company was incorporated in 2017 and is headquartered in San Mateo, California. Address: 1300 South El Camino Real, San Mateo, CA, United States, 94402
Analytics
WallStreet Target Price
4.13 USDP/E ratio
–Dividend Yield
–Current Year
Last Year
Current Quarter
Last Quarter
Current Year
Last Year
Current Quarter
Last Quarter
Key Figures KRON
Dividend Analytics KRON
Dividend growth over 5 years
–Continuous growth
–Payout Ratio 5 years average
–Dividend History KRON
Stock Valuation KRON
Financials KRON
Results | 2019 | Dynamics |